Amesite Inc. reports significant revenue growth and plans to launch an AI-powered EMR by 2026, expanding its healthcare offerings.
Quiver AI Summary
Amesite Inc. (NASDAQ: AMST), a developer of AI-driven enterprise solutions, has reported a significant 69% quarter-over-quarter revenue increase while simultaneously reducing expenses. The company's recent shareholder update highlighted its growing customer base, particularly in post-acute healthcare, and its planned introduction of the first AI-powered electronic medical record (EMR) system by 2026. CEO Dr. Ann Marie Sastry emphasized the importance of innovation in improving healthcare efficiency and quality, noting strong customer satisfaction and engagement with their NurseMagic™ platform. With a focus on operational discipline and the deployment of AI technology, Amesite aims to continue driving revenue growth and expanding its impact in the healthcare sector.
Potential Positives
- Amesite Inc. achieved a significant 69% quarter-over-quarter increase in revenue, indicating strong demand for its services and effective operational execution.
- The company is expanding its customer base and offerings specifically targeting post-acute health businesses across the U.S., which positions it well in a growing market segment.
- Amesite plans to launch what it believes will be the industry's first AI-powered electronic medical record (EMR) platform for post-acute care by 2026, demonstrating innovation and forward-thinking in its technology strategy.
- Excellent product reviews and customer feedback highlight high satisfaction and increased adoption of the NurseMagic™ platform, suggesting a solid foundation for future growth.
Potential Negatives
- While the press release highlights a significant revenue increase, it also indicates reliance on rapid and somewhat speculative technological innovation, which may pose risks if the anticipated products do not meet market needs or face delays.
- The mention of forward-looking statements emphasizes uncertainty, suggesting that actual future performance may differ from claims made in the press release, which could affect investor confidence.
- The focus on developing a new AI-powered EMR platform leaves the company vulnerable to intense competition and potential regulatory hurdles within the healthcare sector, which may slow down implementation or adoption.
FAQ
What recent financial performance did Amesite Inc. report?
Amesite reported a 69% quarter-over-quarter increase in revenue, even with decreased spending.
What is the significance of NurseMagic™ for post-acute healthcare?
NurseMagic™ streamlines healthcare documentation, reducing time from 20 minutes to just 20 seconds and enhances operational efficiency.
What are Amesite's future product plans?
Amesite plans to launch the first AI-powered electronic medical record (EMR) platform for post-acute care by 2026.
How has customer engagement changed recently?
Customer engagement has surged, with an average of 6,500 daily views of the platform video and 28,000 daily website visitors.
What role does AI play in Amesite's strategy?
AI is central to Amesite's strategy for improving healthcare delivery efficiency and quality through its proprietary NurseMagic™ platform.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMST Hedge Fund Activity
We have seen 6 institutional investors add shares of $AMST stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KOVITZ INVESTMENT GROUP PARTNERS, LLC added 32,402 shares (+23.8%) to their portfolio in Q2 2025, for an estimated $87,161
- CITADEL ADVISORS LLC removed 22,992 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $61,848
- TWO SIGMA INVESTMENTS, LP added 21,579 shares (+inf%) to their portfolio in Q2 2025, for an estimated $58,047
- TWO SIGMA SECURITIES, LLC removed 10,589 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $28,484
- HRT FINANCIAL LP removed 10,438 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $28,078
- STATE STREET CORP removed 8,755 shares (-21.7%) from their portfolio in Q2 2025, for an estimated $23,550
- GEODE CAPITAL MANAGEMENT, LLC added 867 shares (+2.8%) to their portfolio in Q2 2025, for an estimated $2,332
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DETROIT, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, announces a 69% QoQ increase in revenue even as it reduced its spending. Amesite also reported expanding its customer base and offerings to post-acute health businesses across the U.S. The Company described these results and its pathway to offer the first AI-powered electronic medical record (EMR) by 2026 in a shareholder update made available yesterday on its website. As part of the shareholder update , Amesite Founder & CEO, Dr. Ann Marie Sastry discussed:
- Summary of FY 2025 10-K and Q1 2026 10-Q: Financial performance was described in the context of methodical execution of platform capabilities demanded by customers.
- Excellent Product Reviews: Customer feedback was described, underscoring high satisfaction and increased adoption in post-acute healthcare segments.
- Efficient Technology Innovation: Rapid deployment of Amesite's proprietary AI technology was described, crediting the AI-forward infrastructure used at the inception of the NurseMagic TM product family.
-
Upcoming Product Plans:
Amesite announced the planned launch of what it believes is the industry’s first AI-powered EMR platform for post-acute care, aiming to deliver operational efficiency for the fastest-growing healthcare segments.
“Our team’s focus on operational discipline has enabled us to drive revenue growth while reducing operating expenses,” said Madison Bush, Director of Corporate Operations. “We are focused on delivering increased value to our shareholders by practicing what we preach: using AI-powered process optimization that continuously increases our business efficiency. Importantly, our customer engagement has accelerated since Q12026, with an average of 6,500 daily views of our platform explainer video and 28,000 daily website visitors.”
“Our increased revenue, of 82% and 69% QoQ for the last two quarters, reflects the strong demand from our customers for NurseMagic TM ’s AI-powered platform support,” added Brandon Owens, VP of Sales. “With a strong technology foundation, and relationships built through delivery of value, we believe that we will grow our business with existing customers and also onboard new, larger clients because of our differentiation in technology.”
“The only way to solve the urgent need to increase the efficiency of delivery of U.S. healthcare, while also improving the quality of care, is through innovation. AI will play the most important role in this transition. By methodically rolling out capabilities and services on our proprietary, AI-powered NurseMagic TM platform, we are working to meet the strong demand for end-to-end, AI-enhanced platform support for post-acute care,” said Dr. Ann Marie Sastry, Founder & CEO.
About Amesite Inc.
Amesite (NASDAQ: AMST) is an AI-driven company with an immediate aim to transform the $330 billion home and healthcare segments. Its flagship product, NurseMagic™, streamlines healthcare documentation, reducing the time required from 20 minutes to just 20 seconds. NurseMagic™ is used by over 100 professions to improve care, enhance operational efficiency and improve financial performance. Built on proprietary AI trained on industry-specific data, NurseMagic meets HIPAA regulations while improving accuracy and efficiency. The platform serves B2B and B2C users across 50 states and 21 countries, offering seamless integration into healthcare workflows and translations to over 50 languages.
Forward-Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations